Deactivating gene could boost immunotherapy for head and neck cancer
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
List view / Grid view
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
Researchers have reviewed lung-on-a-chip technologies, finding they are useful for representing the various disease pathologies.
Why you should link genomics with proteomics to accelerate the search for effective drug targets.
The polymerised form of oestrogen has shown success in mice at preventing further damage to the spinal cord after injury.
Promising results have been shown in an animal model of Alzheimer's disease treated with zinc finger protein transcription factors.
Professor Martin Michaelis and Dr Mark Wass explain why new SARS-CoV-2 variants are emerging around the world and how vaccines will have to adapt in response.
Working with RNA requires rigorous nuclease contamination controls in place. Stock up on Nuclease-Free tubes tips and buffers #Back2Lab
Scientists have developed a model of the early stages of Alzheimer's disease in rhesus macaques to better test new treatments.
Researchers have developed a technique utilising antibodies to tag disease-causing proteins, to treat the underlying causes of disease.
Researchers have developed a CAR T-cell engineering technique to ensure that only cancer cells are targeted, leaving healthy cells alone in solid tumours.
Scientists have created the first model of early human embryos by reprogramming fibroblasts into a blastocyst-like structures.
Dr Ying Kai Chan discusses his latest research into how the delivery of AAV vectors for gene therapies can be made safer and more effective.
A novel machine learning method can explain how glycans stabilise proteins, aiding the discovery and design of protein-based drugs.
SARS-CoV-2 diverts building blocks from glucose production to the assembly of purine bases, researchers have found.
Using X-ray crystallography and simulations, researchers have shown that APT2 is a hybrid between a lipid carrier protein and a hydrolase.